Bet you could use a little air, stu. You're deep underwater on this short and going down for the third time.
As of the latest SEC filings, insiders at Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have decreased their position in the stock by -44.93% over the past 6 months.. Insiders now own 0.30% of total outstanding shares. A round of Cake for the House !
PS this stock generally moves in .25 increments. When it moved definitively above 11.75, you should have known it was going to 12.
Nice to see you're paying close attention, stu - indicates you haven't covered yet.
If this follows the classic pattern, it will halt here just short of 12, looking like it can't break through, in order to let the shorts double up. Then, toward the close,it will break through that level.
I didn't read the report, you ninny. A panel of four GI doctors analyzed all of the available research - including the data in Synergy's NDA to the FDA - and reached the conclusion that they were about the same. If you have a different interpretation of the data, you should write your rebuttal to the editors of The Journal of Gastroenterology, which published the article. Given your vast expertise in the field, no doubt they will retract the article.
Yes, your analysis - as opposed to a panel of four GI doctors - is obviously the objective, unbiased one. The panel concluded, "Based on this analysis, linaclotide and plecanatide have similar efficacy and there is no significant difference in odds of diarrhea adverse events in IBS-C or CIC patients." I'm not sure what you hope to prove by regurgitating all those numbers.
We are talking" LOL ok sure. Muttering in Your Head does not constitute a conversation.
I admit you guys look primed to run that Placebo Company out of business,
as the drug RESPONSE RESULTS were only slightly advantageous to Plec.
EXCEPT for those nasty AE / discontinuation rate ....
PLEC-00 responder 21.0%, 19.5% , 10.2% in 3,6, pbo dose groups
PLEC-03 responder 20.1%, 20.0% , 12.8% in 3,6, pbo dose groups.
LIN 303 responder 21.2%, 19.4 % , 3.3% in 145, 290 mcg, pbo groups
LIN -01 responder 16.0%, 21.3% , 6.0% in 145, 290 mcg, pbo groups
linz primary EP (weaker EP than plec)
Proportion of patients with both three or more complete spontaneous bowel movements (CSBMs)/week and an increase of one or more CSBMs/week from baseline for 9 of 12 weeks.
PLEC primary EP
defined as weekly responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks.
weekly responder (≥ 3 CSBMs/wk, increase ≥1 CSBM
w/o laxative w/in 24 hours, with feeling of complete evacuation.
linz- Diarrhea was the most frequently reported adverse event,
affecting 16.0% , 14.2%, 4.7% of those receiving 145, 290 mcg , pbo.
plec - diarrhea most common AE
affecting 5.9%, 5.7%, 1.3% in 3,6mg, pbo ( Study-00)
affecting 3.2%, 4.5%, 1.3% in 3,6mg, pbo ( Study-03).
Linz discontinuation rates (most commonly diarrhea)
7.9% , 7.3% , 4.2% with 145, 290 mcg, pbo
5.1%, 5.3%, 1.3% in 3,6mg, pbo
(due to diarrhea)
2.7% , 2.6%, 0.4% in 3,6mg, pbo Less
You need to learn how to read a report. Significant positive difference in Plecanatide over linaclotide. Nice try